H.R. 2245 (112th): Preserving Access to Life-Saving Medications Act of 2011

Introduced:
Jun 21, 2011 (112th Congress, 2011–2013)
Sponsor:
Rep. Diana DeGette [D-CO1]
Status:
Died (Referred to Committee)

The bill’s title was written by the bill’s sponsor. H.R. stands for House of Representatives bill.

(About Ads | Go Ad-Free for $5)
Status

This bill was introduced on June 21, 2011, in a previous session of Congress, but was not enacted.

Progress
Introduced Jun 21, 2011
Referred to Committee Jun 21, 2011
Cosponsors
96 cosponsors (73D, 23R) (show)
Committees

House Energy and Commerce

The committee chair determines whether a bill will move past the committee stage.

Full Title

To amend the Federal Food, Drug, and Cosmetic Act to provide the Food and Drug Administration with improved capacity to prevent drug shortages.

Summary

No summaries available.

Text

Read Bill Text »

Last updated Jun 21, 2011.
11 pages

Primary Source

View on THOMAS (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here.

Citation

Click a format for a citation suggestion:

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

6/21/2011--Introduced.
Preserving Access to Life-Saving Medications Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to require the manufacturer of a prescription drug marketed in interstate commerce to notify the Secretary of Health and Human Services (HHS) of a discontinuance or interruption in the manufacture of such drug.
Requires the notification to be submitted six months prior to the date of a discontinuance or interruption, if possible.
Allows the reduction of the notification period if the manufacturer certifies to the Secretary that good cause exists for the reduction.
Authorizes the Secretary to reduce the notification period based on the type of discontinuance or interruption at issue or any other factor.
Treats any information provided to the Secretary under this Act as a trade secret or confidential information.
Establishes civil monetary penalties for violations.
Requires the Secretary to publish on the website of the Food and Drug Administration (FDA) and distribute to the appropriate health care providers and patient organizations information on discontinuances, interruptions, and drug shortages.
Requires the Secretary to notify a manufacturer of:
(1) any determination by the Secretary that a drug may be vulnerable to a drug shortage, and
(2) the Secretary's duty to collaborate to improve continuity of supply.
Prohibits the Secretary from requiring a manufacturer to:
(1) manufacture a drug in the event of a discontinuance or interruption, or
(2) delay or alter a discontinuance or interruption.
Declares that no provision of federal law shall be construed to prohibit a manufacturer from, or penalize a manufacturer for, allocating distribution of its products in order to manage an actual or potential drug shortage.
Requires the Comptroller General to examine issues related to drug shortages.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

The bill contains the following citations to other parts of U.S. law:

United States Code

The United States Code is the compilation of permanent laws enacted by Congress. Temporary and other non-permanent laws do not appear in the United States Code. (About half of the United States Code is the law itself, called positive law. The other half is merely a compilation of the laws but has no legal significance.)